Search

Search Results

1. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A

   More than one percent of people have epilepsy worldwide. Levetiracetam (LEV) is a successful new-generation antiepileptic drug (AED), and its...

   Atsushi Yamagata, Kaori Ito, ... Mikako Shirouzu in Nature Communications

   Article Open access 18 April 2024
   

2. Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)

   Purpose

   Exploring synaptic density changes during brain growth is crucial to understanding brain development. Previous studies in nonhuman primates...

   Samantha Rossano, Takuya Toyonaga, ... Richard E. Carson in European Journal of Nuclear Medicine and Molecular Imaging

   Article 28 May 2022
   

3. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil

   Epilepsy is a common neurological disorder that is primarily treated with antiseizure medications (ASMs). Although dozens of ASMs are available in...

   Peng-Peng Wu, Bi-Rong Cao, ... Zhao-Bing Gao in Neuroscience Bulletin

   Article 28 October 2023
   

4. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

   The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine...

   Sophie E. Holmes, Sjoerd J. Finnema, ... Irina Esterlis in Molecular Psychiatry

   Article 15 February 2022
   

5. Drug characteristics derived from kinetic modeling: combined ¹¹C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A

   Background

   Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure...

   Mika Naganawa, Jean-Dominique Gallezot, ... Richard E. Carson in EJNMMI Research

   Article Open access 08 November 2022
   

6. Synaptic PET Imaging in Neurodegeneration

   Synaptic vesicle glycoprotein 2A (SV2A) is an integral glycoprotein in synaptic vesicle membranes and has been investigated as a potential positron...

   Ming-Kai Chen, David Matuskey, ... Richard E. Carson in Molecular Imaging of Neurodegenerative Disorders

   Chapter 2023
   

7. Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

   Background

   Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer’s disease (AD), which...

   **aoling Wang, **aomin Zhang, ... Peichang Wang in Alzheimer's Research & Therapy

   Article Open access 13 April 2024
   

8. Quantification of SV2A Binding in Rodent Brain Using [¹⁸F]SynVesT-1 and PET Imaging

   Purpose

   Synapse loss is a hallmark of Alzheimer’s disease (AD) and correlates with cognitive decline. The validation of a noninvasive in vivo imaging...

   Pragalath Sadasivam, **aotian T. Fang, ... Zhengxin Cai in Molecular Imaging and Biology

   Article 30 November 2020
   

9. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study

   Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are...

   Ellis Chika Onwordi, Thomas Whitehurst, ... Oliver D. Howes in Translational Psychiatry

   Article Open access 17 July 2021
   

10. Structures of synaptic vesicle protein 2A and 2B bound to anticonvulsants

    Epilepsy is a common neurological disorder characterized by abnormal activity of neuronal networks, leading to seizures. The racetam class of...

    Anshumali Mittal, Matthew F. Martin, ... Jonathan A. Coleman in Nature Structural & Molecular Biology

    Article 19 June 2024
    

11. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [¹¹C]UCB-J PET study

    Purpose

    Here, we evaluate a PET displacement model with a Single-step and Numerical solution in healthy individuals using the synaptic vesicle...

    Maja R. Marstrand-Joergensen, Gjertrud L. Laurell, ... Lars H. Pinborg in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 17 May 2024
    

12. Evaluation of [¹¹C]UCB-A positron emission tomography in human brains

    Background

    In preclinical studies, the positron emission tomography (PET) imaging with [ ¹¹ C]UCB-A provided promising results for imaging synaptic...

    Mengfei **ong, Mark Lubberink, ... Gunnar Antoni in EJNMMI Research

    Article Open access 17 June 2024
    

13. Decreased Synaptic Vesicle Glycoprotein 2A Binding in the Human Postmortem Essential Tremor Cerebellum: Evidence of Reduction in Synaptic Density

    Objective

    Despite being one of the most prevalent neurological diseases, the pathophysiology of essential tremor (ET) is not fully understood....

    Yanghong Yang, Chao Zheng, ... David Matuskey in The Cerebellum

    Article 03 October 2023
    

14. Biallelic variants in the synaptic vesicle glycoprotein 2 A are associated with epileptic encephalopathy

    Synaptic Vesicle Glycoprotein 2 A (SV2A) is a membrane protein of synaptic vesicles and the binding site of antiepileptic drug levetiracetam....

    Almundher Al-Maawali, Fathiya Al-Murshedi, ... Katta M. Girisha in European Journal of Human Genetics

    Article 20 November 2023
    

15. Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

    Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined...

    Zheng Liu, Pyung-Gang Lee, ... Rongsheng ** in Nature Communications

    Article Open access 24 April 2023
    

16. Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218

    Recent genome-wide studies have begun to identify gene variants, expression profiles, and regulators associated with neuroticism, anxiety disorders,...

    Magdalena Jurkiewicz, Dirk Moser, ... Turhan Canli in Translational Psychiatry

    Article Open access 24 August 2020
    

17. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [¹¹C]UCB-J

    Purpose

    Aging is a major societal concern due to age-related functional losses. Synapses are crucial components of neural circuits, and synaptic...

    Takuya Toyonaga, Nikkita Khattar, ... Richard E. Carson in European Journal of Nuclear Medicine and Molecular Imaging

    Article 13 November 2023
    

18. Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

    Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating neuropsychiatric disorders. However, the exact mechanism of action and...

    Annette Johansen, Sophia Armand, ... Gitte M. Knudsen in Molecular Psychiatry

    Article Open access 09 October 2023
    

19. Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations

    Among clinically highly efficient antiseizure medications (ASMs) there are modifiers of the presynaptic release machinery. Of them, levetiracetam and...

    Ewa K. Czapińska-Ciepiela, Jarogniew Łuszczki, ... Władysław Lasoń in Pharmacological Reports

    Article Open access 22 May 2024
    

20. A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders

    Background

    Psychotic disorders have long been considered neurodevelopmental disorders where excessive synaptic pruning and cortical volume loss are...

    Muhammad Omair Husain, Brett Jones, ... George Foussias in BMC Psychiatry

    Article Open access 19 June 2024